Seaport Therapeutics Presents New Preclinical Data on SPT-320 (Glyph Agomelatine) at the Society of Biological Psychiatry (SOBP) Annual Meeting

MOMA Therapeutics to Present Multiple Posters at the American Association for Cancer Research Annual Meeting 2025

Merida Biosciences Launches with $121M to Create Therapeutics for Multiple Autoimmune and Allergic Diseases
 

MOMA Therapeutics Appoints Susan Pandya, M.D., to Board of Directors and Expands Management Team
 

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights